Edition:
United Kingdom

Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

2.33USD
13 Dec 2017
Change (% chg)

-- (--)
Prev Close
$2.33
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
55,484
52-wk High
$2.44
52-wk Low
$0.48

Latest Key Developments (Source: Significant Developments)

Bellerophon Therapeutics reports Q3 loss per share $0.22
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon provides business update and reports third quarter 2017 financial results.Q3 loss per share $0.22.Says ‍ phase 2a study for inopulse met its primary endpoint​.  Full Article

Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filing
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon Therapeutics Inc files to say selling stockholders may offer and resell up to 38.9 million shares of co's common stock - SEC filing.Bellerophon Therapeutics Inc - the selling stockholders will receive all of the proceeds from any sales of the shares offered.  Full Article

Bellerophon qtrly loss per share $0.39
Tuesday, 9 Aug 2016 

Bellerophon Therapeutics Inc : Bellerophon reports second quarter 2016 financial results and provides business update . Qtrly loss per share $0.39 . Company believes it has sufficient funds to satisfy its operating cash needs for at least next 12 months . Believes it has sufficient funds to satisfy its operating cash needs for at least next 12 months .Q2 earnings per share view $-0.51 -- Thomson Reuters I/B/E/S.  Full Article

Bellerophon enrolls first patient in phase 3 trial for pulmonary arterial hypertension
Thursday, 16 Jun 2016 

Bellerophon Therapeutics Inc :1 phase 3 clinical trial for pulmonary arterial hypertension (pah).  Full Article

Bellerophon reports Q1 loss per share $0.54
Tuesday, 10 May 2016 

Bellerophon Therapeutics Inc : Bellerophon reports first quarter 2016 financial results and provides business update . Qtrly loss per share $0.54 .Q1 earnings per share view $-0.66 -- Thomson Reuters I/B/E/S.  Full Article

Bellerophon Therapeutics Inc appoints Fabian Tenenbaum as Chief Financial Officer and Chief Business Officer
Tuesday, 23 Feb 2016 

Bellerophon Therapeutics Inc:Says appointment of Fabian Tenenbaum as Chief Financial Officer and Chief Business Officer.  Full Article

Bellerophon Therapeutics announces positive data from the final analysis of the Phase 2 long-term extension study of INOpulse
Tuesday, 9 Feb 2016 

Bellerophon Therapeutics Inc:Bellerophon Therapeutics announces positive data from the final analysis of the phase 2 long-term extension study of inopulse for treatment of pulmonary arterial hypertension.Says for patients in the long-term extension study, no significant safety issues have been found.Says only 2 serious adverse events have been reported as possibly related.Says these data directly support the design of the planned phase III trial.  Full Article

BRIEF-Bellerophon Appoints Ted Wang To Its Board Of Directors

* BELLEROPHON APPOINTS TED WANG, PH.D., OF PUISSANCE CAPITAL MANAGEMENT, TO ITS BOARD OF DIRECTORS